Geoffrey R. Oxnard, MD
Preliminary research has shown the potential application of cell-free DNA (cfDNA) in detecting cancer and directing treatment decisions, explained Geoffrey R. Oxnard, MD; however, the approach requires clinical validation before it can be used in practice.
, Oxnard, an associate professor of medicine at Harvard Medical School and a thoracic oncologist at Dana-Farber Cancer Institute, discussed the use of cfDNA as a potential method of cancer detection and subsequent assessment of treatment response in patients with solid and hematologic malignancies.
OncLive: What are some ways in which cfDNA is being used to detect cancer?
: CancerSEQ is an assay that uses a next-generation sequencing (NGS) panel to look for key mutations in addition to proteomics. GRAIL is developing a broad genome-wide assay that looks across the entire genome for any abnormal signals; this is done by deleting the white cell signals and leaving the hidden signal that may be related to cancer. [However], there's a long road ahead of us before we will be able to develop a test that can help healthy patients know whether they have cancer or not.
... to read the full story